Qian Shi

List of Publications by Year
in descending order

186 papers	7,986 citations	50170 46 h-index	53109 85 g-index
187 all docs	187 docs citations	187 times ranked	10705 citing authors

#	Article	IF	Citations
1	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 2018, 378, 1177-1188.	13.9	699
2	Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. Journal of Clinical Oncology, 2012, 30, 263-267.	0.8	483
3	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	5.1	442
4	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. JAMA Surgery, 2016, 151, e161137.	2.2	365
5	Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncology, The, 2015, 16, 1537-1546.	5.1	326
6	Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design. Annals of Surgical Oncology, 2013, 20, 2787-2795.	0.7	302
7	A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial. Annals of Surgical Oncology, 2012, 19, 384-391.	0.7	291
8	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. Gastroenterology, 2015, 148, 88-99.	0.6	273
9	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€"Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	12.5	218
10	Prognostic Value of<i>BRAFÂ</i>andÂ<i>KRAS</i>ÂMutations in MSI and MSS Stage III Colon Cancer. Journal of the National Cancer Institute, 2017, 109, djw272.	3.0	201
11	Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer, 2017, 17, 505.	1.1	166
12	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood, 2020, 135, 2041-2048.	0.6	158
13	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Lancet Oncology, The, 2020, 21, 1620-1629.	5.1	152
14	DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	136
15	Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas. Clinical Cancer Research, 2012, 18, 546-554.	3.2	129
16	<i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i>â€"Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). Clinical Cancer Research, 2014, 20, 3033-3043.	3.2	129
17	Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas. JAMA Oncology, 2022, 8, 1263.	3.4	107
18	Treatment of acute iliofemoral deep vein thrombosis. Journal of Vascular Surgery, 2012, 55, 1463-1473.	0.6	106

#	Article	IF	Citations
19	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. JAMA Oncology, 2018, 4, 379.	3.4	104
20	Racial Differences in <i>BRAF</i>/<i>KRAS</i> Mutation Rates and Survival in Stage III Colon Cancer Patients. Journal of the National Cancer Institute, 2015, 107, djv186.	3.0	98
21	Aspirin for the Primary Prevention of Cardiovascular Events. Diabetes Care, 2009, 32, 2300-2306.	4.3	93
22	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2019, 5, 1582.	3.4	91
23	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	0.8	87
24	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology, 2017, 35, 552-560.	0.8	87
25	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology, 2021, 39, 642-651.	0.8	84
26	Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With Esophageal Adenocarcinoma. Journal of Clinical Oncology, 2012, 30, 3932-3938.	0.8	83
27	Hyperglycemia in Patients Undergoing Cerebral Aneurysm Surgery: Its Association With Long-term Gross Neurologic and Neuropsychological Function. Mayo Clinic Proceedings, 2008, 83, 406-417.	1.4	82
28	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. JAMA Oncology, 2017, 3, 472.	3.4	82
29	Unsafe rear-end collision avoidance in Alzheimer's disease. Journal of the Neurological Sciences, 2006, 251, 35-43.	0.3	72
30	Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. International Journal of Clinical Oncology, 2009, 14, 102-111.	1.0	70
31	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	3.3	69
32	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. Journal of Clinical Oncology, 2010, 28, 460-465.	0.8	67
33	PERIOPERATIVE FEVER AND OUTCOME IN SURGICAL PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE. Neurosurgery, 2009, 64, 897-908.	0.6	65
34	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 3656-3663.	0.8	65
35	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. Journal of Clinical Oncology, 2021, 39, 631-641.	0.8	63
36	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2021, 325, 1277.	3.8	63

#	Article	IF	Citations
37	Prognostic Impact of Body Mass Index Stratified by Smoking Status in Patients With Esophageal Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 4561-4567.	0.8	61
38	Mutation–specific antibody detects mutant BRAF^{V600E} protein expression in human colon carcinomas. Cancer, 2013, 119, 2765-2770.	2.0	60
39	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL). Journal of Clinical Oncology, 2018, 36, 2593-2602.	0.8	59
40	Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis. Clinical Cancer Research, 2019, 25, 125-133.	3.2	57
41	Bonferroni–based correction factor for multiple, correlated endpoints. Pharmaceutical Statistics, 2012, 11, 300-309.	0.7	56
42	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood, 2022, 139, 1684-1693.	0.6	56
43	Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. Journal of Clinical Oncology, 2014, 32, 3507-3507.	0.8	53
44	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). Clinical Trials, 2019, 16, 165-175.	0.7	52
45	Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy–An Aide et Recherche en Cancérologie Digestive Group Study. Journal of Clinical Oncology, 2011, 29, 4199-4204.	0.8	51
46	Distribution of Body Fat and Its Influence on Esophageal Inflammation and Dysplasia in Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2012, 10, 728-734.	2.4	51
47	Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147. Journal of Clinical Oncology, 2013, 31, 2016-2023.	0.8	49
48	Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. Journal of Clinical Oncology, 2018, 36, 3120-3125.	0.8	45
49	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. Journal of Clinical Oncology, 2021, 39, 4009-4019.	0.8	45
50	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34â€‰640 Patients in the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 400-407.	3.0	44
51	Beta–blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	2.0	41
52	Association Study of the let-7 miRNA-Complementary Site Variant in the 3â€² Untranslated Region of the *KRAS* Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial). Clinical Cancer Research, 2014, 20, 3319-3327.	3.2	40
53	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa023.	1.4	36
54	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. Journal of Clinical Oncology, 2012, 30, 2334-2339.	0.8	34

#	Article	IF	Citations
55	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist, 2016, 21, 1509-1521.	1.9	33
56	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. Journal of Clinical Oncology, 2017, 35, LBA1-LBA1.	0.8	31
57	Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Annals of Surgical Oncology, 2011, 18, 3261-3270.	0.7	30
58	Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).. Journal of Clinical Oncology, 2019, 37, 3501-3501.	0.8	30
59	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29
60	Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients. Pharmacogenetics and Genomics, 2016, 26, 133-137.	0.7	28
61	Developing an FHIR-Based Computational Pipeline for Automatic Population of Case Report Forms for Colorectal Cancer Clinical Trials Using Electronic Health Records. JCO Clinical Cancer Informatics, 2020, 4, 201-209.	1.0	28
62	The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database. Clinical Colorectal Cancer, 2013, 12, 179-187.	1.0	27
63	*HER‑2/neu* gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer, 2014, 120, 415-424.	2.0	27
64	Bayesian adjusted R^2 for the meta‑analytic evaluation of surrogate time‑to‑event endpoints in clinical trials. Statistics in Medicine, 2012, 31, 743-761.	0.8	26
65	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	3.0	25
66	Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	23	
67	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. Computational Statistics and Data Analysis, 2011, 55, 2748-2757.	0.7	23
68	Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Annals of Oncology, 2020, 31, 480-486.	0.6	23
69	Marine omega‑3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). International Journal of Cancer, 2019, 145, 380-389.	2.3	22
70	Traffic-Entry Behavior and Crash Risk for Older Drivers with Impairment of Selective Attention. Perceptual and Motor Skills, 2006, 102, 632-644.	0.6	19
71	Anorectal Function and Quality of Life in Patients With Early Stage Rectal Cancer Treated With Chemoradiation and Local Excision. Diseases of the Colon and Rectum, 2017, 60, 459-468.	0.7	19
72	Perioperative Gemcitabine‰+‰Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology, 2019, 26, 4489-4497.	0.7	19

#	Article	IF	Citations
73	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. Clinical Cancer Research, 2014, 20, 4361-4369.	3.2	18
74	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. European Journal of Cancer, 2021, 144, 101-112.	1.3	18
75	Persistence of Nondysplastic Barrettâ€™s Esophagus Is Not Protective Against Progression to Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2017, 15, 950-952.	2.4	17
76	Modeling cancer clinical trials using HL7 FHIR to support downstream applications: A case study with colorectal cancer data. International Journal of Medical Informatics, 2021, 145, 104308.	1.6	17
77	Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.. Journal of Clinical Oncology, 2015, 33, 4008-4008.	0.8	17
78	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. Journal of Clinical Oncology, 2017, 35, LBA1-LBA1.	0.8	17
79	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. International Journal of Cancer, 2016, 139, 986-995.	2.3	16
80	Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scandinavian Journal of Gastroenterology, 2012, 47, 356-362.	0.6	15
81	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer, 2020, 130, 63-71.	1.3	15
82	Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts).. Journal of Clinical Oncology, 2015, 33, 8504-8504.	0.8	14
83	Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database.. Journal of Clinical Oncology, 2018, 36, 728-728.	0.8	14
84	Overview: biostatistician's role in oncology clinical trials-strive for sound, efficient and practical studies. Chinese Clinical Oncology, 2014, 3, 1.	0.4	14
85	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	1.3	13
86	Impact of diabetes and metformin use on recurrence and outcome in stage IIâ€"III colon cancer patientsâ€"A pooled analysis of three adjuvant trials. European Journal of Cancer, 2022, 166, 100-111.	1.3	13
87	Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. Cancers, 2020, 12, 1990.	1.7	12
88	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1705-1713.	3.0	12
89	Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). European Journal of Cancer, 2021, 150, 214-223.	1.3	12
90	Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study. Clinical Trials, 2010, 7, 686-695.	0.7	11

#	ARTICLE	IF	CITATIONS
91	Combining Molecular Markers With the TNM Staging System to Improve Prognostication in Stage II and III Colon Cancer: Are We Ready Yet?. Journal of the National Cancer Institute, 2012, 104, 1616-1618.	3.0	11
92	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 696-703.	1.1	11
93	Statistical Considerations for the Next Generation of Clinical Trials. Seminars in Oncology, 2011, 38, 598-604.	0.8	10
94	Center-within-trial versus trial-level evaluation of surrogate endpoints. Computational Statistics and Data Analysis, 2014, 78, 1-20.	0.7	10
95	Isocitrate Dehydrogenaseâ€"Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precision Oncology, 2022, 6, e2100156.	1.5	10
96	A Comparison of the Number of Hours of Sleep in High School Students Who Took Advanced Placement and/or College Courses and Those Who Did Not. Journal of School Nursing, 2008, 24, 417-424.	0.9	9
97	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).. Journal of Clinical Oncology, 2017, 35, 3579-3579.	0.8	9
98	Relapsed/Refractory International Prognostic Index (R/<scp>Râ€IPI</scp>): An international prognostic calculator for relapsed/refractory diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8
99	Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.. Journal of Clinical Oncology, 2016, 34, 3518-3518.	0.8	8
100	Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	8
101	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. Oncologist, 2017, 22, 1415-1418.	1.9	7
102	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 2717-2723.e3.	2.4	7
103	Mining the ACCENT database: a review and update. Chinese Clinical Oncology, 2013, 2, 18.	0.4	7
104	Evaluation of Continuous Tumor-Sizeâ€"Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2019, 2, e1911750.	2.8	6
105	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. Journal of Clinical Oncology, 2015, 33, 3507-3507.	0.8	6
106	Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. Journal of Clinical Oncology, 2018, 36, 3599-3599.	0.8	6
107	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancerâ‰¥ 70 years. European Journal of Cancer, 2022, 163, 1-15.	1.3	6
108	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 2022, 114, 60-67.	3.0	5

#	ARTICLE	IF	CITATIONS
109	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood, 2016, 128, 3027-3027.	0.6	5
110	Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.. Journal of Clinical Oncology, 2019, 37, 3502-3502.	0.8	5
111	The Relationship of the Intensity of Posttreatment Prostate-Specific Antigen Surveillance and Prostate Cancer Outcomes: Results From a Population-Based Cohort. Mayo Clinic Proceedings, 2012, 87, 540-547.	1.4	4
112	A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. Journal of Biopharmaceutical Statistics, 2018, 28, 451-462.	0.4	4
113	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. JCO Precision Oncology, 2020, 4, 116-127.	1.5	4
114	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectrum, 2021, 5, pkab070.	1.4	4
115	Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database.. Journal of Clinical Oncology, 2016, 34, 656-656.	0.8	4
116	Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.. Journal of Clinical Oncology, 2018, 36, 3603-3603.	0.8	4
117	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. Journal of Clinical Oncology, 2019, 37, 3520-3520.	0.8	4
118	Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database.. Journal of Clinical Oncology, 2017, 35, 3582-3582.	0.8	4
119	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology, 2022, , .	1.5	4
120	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. Clinical Colorectal Cancer, 2015, 14, 99-105.	1.0	3
121	Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. Journal of Clinical Oncology, 2016, 34, 3949-3950.	0.8	3
122	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. Clinical Trials, 2021, 18, 51-60.	0.7	3
123	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110205.	1.4	3
124	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. Blood, 2016, 128, 1102-1102.	0.6	3
125	Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).. Journal of Clinical Oncology, 2015, 33, 3590-3590.	0.8	3
126	Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database.. Journal of Clinical Oncology, 2017, 35, 766-766.	0.8	3

#	ARTICLE	IF	CITATIONS
127	Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3525-3525.	0.8	3
128	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	1.4	3
129	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. Journal of Clinical Oncology, 2014, 32, 3538-3538.	0.8	2
130	Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. Journal of Clinical Oncology, 2014, 32, 3578-3578.	0.8	2
131	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. Journal of Clinical Oncology, 2015, 33, 3506-3506.	0.8	2
132	Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance).. Journal of Clinical Oncology, 2015, 33, 3531-3531.	0.8	2
133	Alliance for clinical trials in oncology trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.. Journal of Clinical Oncology, 2017, 35, TPS4151-TPS4151.	0.8	2
134	Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 2018, 36, 3582-3582.	0.8	2
135	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. Journal of Clinical Oncology, 2018, 36, 612-612.	0.8	2
136	Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.. Journal of Clinical Oncology, 2020, 38, 4003-4003.	0.8	2
137	Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).. Journal of Clinical Oncology, 2017, 35, 3516-3516.	0.8	2
138	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
139	End of induction positron emission tomography complete response (PETâ€CR) as a surrogate for progressionâ€free survival in previously untreated follicular lymphoma. British Journal of Haematology, 2022, 198, 333-337.	1.2	2
140	Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise. Clinical Cancer Research, 0, , OF1-OF3.	3.2	2
141	From isolated hypotheses to connected practical studies: statisticiansâ€™ role in a seamless targeted therapy development. Future Medicinal Chemistry, 2012, 4, 943-945.	1.1	1
142	Milestone prediction for timeâ€toâ€event endpoint monitoring in clinical trials. Pharmaceutical Statistics, 2019, 18, 433-446.	0.7	1
143	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. Blood, 2016, 128, 4196-4196.	0.6	1
144	HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods.. Journal of Clinical Oncology, 2013, 31, 2-2.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance).. Journal of Clinical Oncology, 2015, 33, 1508-1508.	0.8	1
146	HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147).. Journal of Clinical Oncology, 2015, 33, 508-508.	0.8	1
147	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.. Journal of Clinical Oncology, 2019, 37, 3525-3525.	0.8	1
148	Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].. Journal of Clinical Oncology, 2014, 32, 3512-3512.	0.8	1
149	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. Journal of Clinical Oncology, 2015, 33, 666-666.	0.8	1
150	Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.. Journal of Clinical Oncology, 2016, 34, 3600-3600.	0.8	1
151	Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance A021302) Impac.. Journal of Clinical Oncology, 2017, 35, TPS4135-TPS4135.	0.8	1
152	Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations. Journal of Neuro-Oncology, 2017, 134, 551-557.	1.4	1
153	Variability of pelvic MRI performance in a prospective multicenter rectal cancer trial NCCTG N1048 (Alliance).. Journal of Clinical Oncology, 2018, 36, e18783-e18783.	0.8	1
154	A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.. Journal of Clinical Oncology, 2019, 37, 32-32.	0.8	1
155	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. Journal of Clinical Oncology, 2020, 38, 4099-4099.	0.8	1
156	Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies. Chinese Clinical Oncology, 2022, 11, 7-7.	0.4	1
157	Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. Journal of Clinical Oncology, 2022, 40, 3572-3572.	0.8	1
158	Statistical Evaluation of the Use of Concurrent Controls in Treatment Screening Studies. Clinical and Translational Science, 2013, 6, 323-330.	1.5	0
159	343 Persistence of Non Dysplastic Barrett's Esophagus Is Not Protective Against Progression to Adenocarcinoma: Results From a Prospective Be-EAC Registry. Gastrointestinal Endoscopy, 2015, 81, AB140.	0.5	0
160	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. Current Colorectal Cancer Reports, 2016, 12, 251-259.	1.0	0
161	Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?â€"Reply. JAMA Oncology, 2017, 3, 1285.	3.4	0
162	Reply to H.J.A. Adams et al. Journal of Clinical Oncology, 2019, 37, 526-527.	0.8	0

#	ARTICLE	IF	CITATIONS
163	A Statistical Method for Association Analysis of Cell Type Compositions. Statistics in Biosciences, 2021, 13, 373-385.	0.6	0
164	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. Journal of Clinical Oncology, 2021, 39, 10-10.	0.8	0
165	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis.. Journal of Clinical Oncology, 2012, 30, 443-443.	0.8	0
166	Racial differences in <i>KRAS</i>/<i>BRAF</i> mutation rates and survival in colon cancer (NCCTG Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	0
167	Abstract 5102: Telomeres and survival in stage III colon cancers: Findings from NCCTG N0147 (Alliance) study. , 2014, , .		0
168	Comparison of HER2 gene amplification (AMP) in primary esophageal and gastroesophageal junction adenocarcinomas (EAC) and their metastatic regional lymph nodes (MLNs).. Journal of Clinical Oncology, 2015, 33, 4059-4059.	0.8	0
169	Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database.. Journal of Clinical Oncology, 2016, 34, 658-658.	0.8	0
170	Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147.. Journal of Clinical Oncology, 2016, 34, e15148-e15148.	0.8	0
171	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	0.6	0
172	Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance).. Journal of Clinical Oncology, 2017, 35, 3604-3604.	0.8	0
173	Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.. Journal of Clinical Oncology, 2018, 36, 724-724.	0.8	0
174	Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.. Journal of Clinical Oncology, 2018, 36, 617-617.	0.8	0
175	Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.. Journal of Clinical Oncology, 2018, 36, e16035-e16035.	0.8	0
176	Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).. Journal of Clinical Oncology, 2018, 36, 3583-3583.	0.8	0
177	CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).. Journal of Clinical Oncology, 2018, 36, 3598-3598.	0.8	0
178	A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).. Journal of Clinical Oncology, 2018, 36, 4112-4112.	0.8	0
179	Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).. Journal of Clinical Oncology, 2018, 36, e16107-e16107.	0.8	0
180	Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.. Journal of Clinical Oncology, 2019, 37, 3539-3539.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.. Journal of Clinical Oncology, 2019, 37, 3583-3583.	0.8	0
182	Reply to A. Smith et al. Journal of Clinical Oncology, 2022, , JCO2200246.	0.8	0
183	Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials. Statistical Methods in Medical Research, 0, , 096228022211026.	0.7	0
184	Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.. Journal of Clinical Oncology, 2022, 40, 3606-3606.	0.8	0
185	Effect of primary tumor sidedness on the association of tumor-infiltrating lymphocytes with survival of patients with stage III colon cancer (NCCTG N0147) [alliance].. Journal of Clinical Oncology, 2022, 40, 3525-3525.	0.8	0
186	First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. Journal of Clinical Oncology, 2022, 40, 3578-3578.	0.8	0